



LUNG-MAP

A lung cancer precision medicine trial

VOLUME 15 | WINTER 2020

NEWSLETTER

WWW.LUNG-MAP.ORG

We Made It Through Together

The cancer research community faced enormous challenges in 2020, with COVID stopping or slowing clinical trials at many cancer centers and community hospitals. Yet you screened over 900 patients to Lung-MAP this year, a significant achievement in the face of adversity. Thank you!

By offering this precision medicine trial to your patients, you're giving them access to new targeted drugs and immunotherapies — and giving them a second or third-line treatment choice. I'm proud that Lung-MAP has tested 12 treatments in five years.


Looking ahead to 2021, we've got two great new sub-studies coming — a targeted drug from Amgen for patients with previously treated stage IV or recurrent KRAS G12C mutated

non-squamous, non-small cell lung cancer expected in January 2021 and a non-match study testing an ImmunityBio immunotherapy expected to roll out in late summer of 2021.



And we'll be kicking the new year off with high-profile presentations at the World Conference on Lung Cancer to be held January 28-31. Some of our study chairs will present results of three translational medicine studies — our first batch ever.

On behalf of the entire Lung-MAP team, we are grateful to you. You helped us make it through a difficult year — and moved lung cancer medicine forward.



Roy Herbst, MD
Lung-MAP Study Chair

Lung-MAP Lands in Lancet Oncology

Mary Redman, PhD, is the lead statistician responsible for Lung-MAP's many study designs, and has set the standard for master protocols not only in lung cancer but in many cancers and in other diseases.

In October, Redman published a report in The Lancet Oncology of the first iteration of Lung-MAP, when the trial focused on squamous cell lung cancer.

In the article, [which you can read here](#), Redman explains the umbrella design and how it creates options for every patient, whether they match to a targeted drug sub-study or a non-match drug.

A statistician based at Fred Hutchinson Cancer Research Center, Redman and the Lancet article are highlighted in a terrific online article on the Fred Hutch website. [Read it here](#).



Mary Redman, PhD
Lung-MAP Study Chair for Lung-MAP's statistical design

LEARN MORE AT
WWW.LUNG-MAP.ORG



Welcome New Lung-MAP Leaders

Jyoti Patel, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Lung-MAP vice chair

David Kozono, MD, PhD, Dana-Farber, Lung-MAP translational medicine chair

Ticiana Leal, MD, University of Wisconsin-Madison, Lung-MAP ECOG-ACRIN medical oncology chair

Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Lung-MAP drug selection committee chair

As of 12/8/20, the new Lung-MAP protocol has logged:

1763 screening registrations | **914** sub-study assignments | **273** sub-study registrations

Over 900 screening registrations in 2020 alone

TOP ACCRUING SITES*

1. UPMC Hillman Cancer Center	Pittsburgh, PA	99
2. Wilmot Cancer Institute	Rochester, NY	30
2. Mercy Medical Center	Canton, OH	30
3. Missouri Baptist Medical Center	St. Louis, MO	29
4. Good Samaritan Hospital	Cincinnati, OH	24
4. Stephenson Cancer Center	Oklahoma City, OK	24
5. Markey Cancer Center	Lexington, KY	23
5. Essentia Health	Duluth, MN	23
5. UNM Comprehensive Cancer Center	Albuquerque, NM	23
6. Northside Hospital Cancer Institute	Atlanta, GA	21
6. Roswell Park Comprehensive Cancer Center	Buffalo, NY	21
7. Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago, IL	20
7. Lahey Hospital & Medical Center	Burlington, MA	20
8. UC Davis Comprehensive Cancer Center	Sacramento, CA	18
8. Palo Alto Medical Foundation – Santa Cruz	Santa Cruz, CA	18
8. VA Connecticut Healthcare System	West Haven, CT	18
8. Holden Comprehensive Cancer Center	Iowa City, IO	18
8. Oncology Associates at Mercy Medical Center	Cedar Rapids, IA	18
9. Sparrow Herbert-Herman Cancer Center	Lansing, MI	17
9. Mercy Hospital Saint Louis	St. Louis, MO	17
10. Medical Oncology Hematology Consultants	Newark, DE	16
10. Baystate Medical Center	Springfield, MA	16
10. IHA Hematology Oncology at St. Joe's Ann Arbor	Ypsilanti, MI	16

**As of 12/8/20*

CONTACT US

Protocol & Regulatory Questions

lgildner@swog.org or mnorman@swog.org

Eligibility & Data Submission Questions

LUNGMAPQuestion@crab.org

General Medical Questions

LUNGMAP@swog.org

Central Monitoring Questions

centralmonitorquestion@crab.org

Quality Assurance Auditing Questions

qamail@swog.org

Funding Questions

funding@swog.org